Targeting Diabetes from the Negev
October 17, 2013
The NY Jewish Week — When Andy David’s nine-year-old daughter was diagnosed with type 1 diabetes, the Israeli diplomat used his medical background to search for an unconventional treatment that would spare her from daily doses of insulin.
David, who is currently Israel’s consul general for the Pacific Northwest, soon learned about groundbreaking research being conducted by BGU’s Dr. Eli Lewis and his team at the University’s Clinical Islet Laboratory that shows great promise for patients in the early stages of type 1 diagnosis.
His daughter (unnamed her for security reasons) underwent eight weeks of transfusions of alpha 1, an anti-inflammatory drug generally used to treat emphysema.
“That was two and a half-years ago, and she has not had to have insulin,” said David, who is a non-practicing dentist and also has a degree in medical science.
He praised the researchers at BGU for their groundbreaking work. “Their goal is not to manage diabetes but to eliminate it,” he said.
Read more on The Jewish Week website >>
Stories Like This
